What is the 13F Pro Quality Score for SKIN?

13F Pro ranks SkinHealth Systems Inc. (SKIN) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View SKIN's current score at https://13fpro.ai/research/SKIN (free sign-up required for the full ranking).

Which hedge funds own the most SKIN stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of SKIN include Capricorn Fund Managers Ltd, FMR, BlackRock,. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/research/SKIN as soon as new 13F filings post.

Where does 13F Pro source SKIN data?

All SkinHealth Systems Inc. fundamentals and ownership data come directly from SEC EDGAR. SkinHealth Systems Inc. files with the SEC under CIK 1818093. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is SKIN in?

SkinHealth Systems Inc. (SKIN) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is SKIN research updated on 13F Pro?

SKIN's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

SkinHealth Systems Inc.(SKIN)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1818093 SKIN stock profile & AI dashboard →

13F Pro Quality Score

32.1/100

Rank #2,287 of 2,879 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

9.4/100

Profitability

44.5/100

Balance Sheet

30.5/100

Earnings Quality

30.0/100

Free Cash Flow

53.0/100

Institutional Flow

33.2/100

Revenue Scale

28.8/100

Dilution Risk

25.9/100

SKIN Stock Analysis & AI Quality Score

AI stock analysis and institutional research for SkinHealth Systems Inc. (SKIN), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores SKIN at 32.1/100 on a 32-signal composite quality model, placing it at rank #2,287 of 2,879 stocks — the bottom half of the AI-ranked universe. Areas of concern include revenue growth (9.4) and revenue scale (28.8), which score below median versus the broader universe. Shareholder dilution risk is elevated at 25.9/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), SkinHealth Systems Inc. reports quarterly revenue of $64.9M, net income of $-6.6M, an operating margin of -2.8%. Top institutional holders of SKIN by reported 13-F value include Capricorn Fund Managers Ltd, FMR, BlackRock,, based on the most recent SEC filings. SKIN trades on the Nasdaq exchange and files with the SEC under CIK 1818093. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate SKIN daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for SkinHealth Systems Inc. directly from SEC EDGAR. SkinHealth Systems Inc.'s 13F Pro composite quality score has ranged between 22 and 52 since 2022, currently 32.1 — an improving long-term trajectory across 23 quarterly and live scoring snapshots.

Revenue

Q1 2026

$64.9M

Net Income

Q1 2026

$-6.6M

Free Cash Flow

Q1 2026

$-5.8M

Operating Margin

Q1 2026

-2.8%

ROIC

Q1 2026

-3.3%

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

-10.0% YoY

$300.8MFY 2025

FY22 $365.9MFY23 $398.0MFY24 $334.3MFY25 $300.8M

Net Income

+67.4% YoY

$-9.5MFY 2025

FY22 $44.2MFY23 $-100.1MFY24 $-29.1MFY25 $-9.5M

Operating Income

+69.3% YoY

$-20.8MFY 2025

FY22 $-25.8MFY23 $-130.9MFY24 $-67.8MFY25 $-20.8M

EPS (Diluted)

+55.6% YoY

$-0.16FY 2025

FY22 $-0.23FY23 $-0.76FY24 $-0.36FY25 $-0.16

Total Assets

-27.1% YoY

$499.8MFY 2025

FY22 $1.00BFY23 $929.1MFY24 $685.7MFY25 $499.8M

Total Debt

—FY 2025

FY22 —FY23 —FY24 $552.2MFY25 —

Op. Cash Flow

+132.3% YoY

$37.5MFY 2025

FY22 $-106.6MFY23 $21.8MFY24 $16.1MFY25 $37.5M

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Revenue	$300.8M -10.0%	$334.3M -16.0%	$398.0M +8.8%	$365.9M +40.7%	$260.1M +118.4%	$119.1M
Net Income	$-9.5M +67.4%	$-29.1M +70.9%	$-100.1M -326.3%	$44.2M -88.3%	$378.7M +1398.0%	$-29.2M
Operating Income	$-20.8M +69.3%	$-67.8M +48.2%	$-130.9M -406.6%	$-25.8M +35.3%	$-39.9M -132.4%	$-17.2M
EPS (Diluted)	$-0.16 +55.6%	$-0.36 +52.6%	$-0.76 -230.4%	$-0.23 +93.8%	$-3.71 -336.5%	$-0.85
Total Assets	$499.8M -27.1%	$685.7M -26.2%	$929.1M -7.4%	$1.00B -17.7%	$1.22B +447.0%	$222.8M
Total Debt	—	$552.2M	—	—	—	—
Operating Cash Flow	$37.5M +132.3%	$16.1M -25.8%	$21.8M +120.4%	$-106.6M -275.9%	$-28.4M -128.1%	$-12.4M

AI Insight: SKIN Financial Trends

Revenue declined 29% from Q2 2024 to Q1 2026 while operating losses persisted despite brief Q4 2025 breakeven.

• Revenue fell from $91M in Q2 2024 to $65M in Q1 2026, marking persistent decline.

• Operating income improved from -$22M losses to breakeven $0M in Q4 2025 before declining again.

• Operating cash flow turned negative to -$6M in Q1 2026, first negative quarter in the series.

⚠ Total debt of $363M appeared in Q2 2025 then disappeared, suggesting significant financing event needs clarification.

⚠ Equity declined from $69M to $55M over eight quarters despite periodic net income gains.

AI Insight: SKIN Ratio Trends

SkinHealth achieved its first quarterly operating profit in Q4 2025 but remains deeply unprofitable with deteriorating ROIC trends.

• Operating margin improved from -27.3% in Q3 2024 to 0.2% in Q4 2025, marking the first profitable quarter.

• ROE losses narrowed significantly from -122.5% in Q3 2024 to -48.0% in Q1 2026.

• Company remains loss-making with TTM operating margin of -3.6% and net profit margin of -2.0%.

⚠ ROIC deteriorated sharply from 1.1% in Q4 2025 to -13.0% in Q1 2026 after brief positive territory.

⚠ Operating margin turned negative again to -2.8% in Q1 2026 after achieving breakeven in Q4 2025.

Get alerted when SKIN's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for SkinHealth Systems Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of SKIN

Capricorn Fund Managers Ltd
$17.3M19,404,192 sh
FMR LLC
$15.3M17,183,231 sh
BlackRock, Inc.
$6.5M7,357,614 sh
MILLENNIUM MANAGEMENT LLC
$5.1M5,717,460 sh
Woodline Partners LP
$5.1M5,698,984 sh
UBS Group AG
$3.2M3,542,164 sh
VANGUARD CAPITAL MANAGEMENT LLC
$3.1M3,441,008 sh
GEODE CAPITAL MANAGEMENT, LLC
$2.0M2,241,596 sh
D. E. Shaw & Co., Inc.
$1.7M1,898,475 sh
STATE STREET CORP
$1.7M1,884,027 sh

Fund	Value	Shares
Capricorn Fund Managers Ltd	$17.3M	19,404,192
FMR LLC	$15.3M	17,183,231
BlackRock, Inc.	$6.5M	7,357,614
MILLENNIUM MANAGEMENT LLC	$5.1M	5,717,460
Woodline Partners LP	$5.1M	5,698,984
UBS Group AG	$3.2M	3,542,164
VANGUARD CAPITAL MANAGEMENT LLC	$3.1M	3,441,008
GEODE CAPITAL MANAGEMENT, LLC	$2.0M	2,241,596
D. E. Shaw & Co., Inc.	$1.7M	1,898,475
STATE STREET CORP	$1.7M	1,884,027

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put SKIN on your watchlist

Track score changes the day SkinHealth Systems Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is SKIN a good stock to buy?

13F Pro's AI-powered analysis of SkinHealth Systems Inc. (SKIN) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for SKIN are available on the SKIN stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own SKIN?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling SKIN. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of SkinHealth Systems Inc.'s investment landscape.